Trials / Unknown
UnknownNCT05429554
The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients
The Impact of Metformin and Dipeptidyl Peptidase- 4 Inhibitors on Cognitive Function and Cardiovascular Protection in Type 2 Diabetic Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- MTI University · Academic / Other
- Sex
- All
- Age
- 40 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The Impact of Metformin and Dipeptidyl Peptidase- 4 Inhibitors on Cognitive Function and cardiovascular protection in Type 2 Diabetic Patients
Detailed description
This study aims to investigate the effect of daily oral DPP4 inhibitors and oral metformin on neurodegeneration in type 2 diabetic patients. This study aims to compare between the cardiovascular protective properties of DPP-4 inhibitors and Metformin in type 2 diabetic patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vildagliptin | observe the effect of vildagliptin on cognitive function and cardiovascular in diabetic patients |
Timeline
- Start date
- 2022-06-01
- Primary completion
- 2022-09-01
- Completion
- 2022-09-01
- First posted
- 2022-06-23
- Last updated
- 2022-06-23
Locations
1 site across 1 country: Egypt
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05429554. Inclusion in this directory is not an endorsement.